Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Photodiagnosis Photodyn Ther ; 41: 103302, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-36690194

RESUMO

BACKGROUND: Patients with erythropoietic protoporphyria (EPP) are hypersensitive to long wave ultraviolet (UVA) radiation and visible light and they experience severe skin pain by light exposure. The patients have very limited treatment options. Sunless skin tanning with dihydroxyacetone (DHA) is now being investigated as a possible treatment modality of skin photosensitivity in EPP. METHODS: We simulated the theoretical light protection factor provided by DHA application. In addition, we present 19 cases with EPP who were treated at our department with DHA weekly during spring and summer from 2018 to 2021 inclusive. RESULTS: The protection factor against UVA and visible light was estimated to approximately two. Out of the 19 patients with EPP who were treated with DHA in 2018, 11 patients experienced a sustained good effect and continued to use the treatment on a weekly basis in the spring and summer of 2019, 2020, and 2021. CONCLUSION AND PERSPECTIVES: Both the theoretical estimates and the uncontrolled study suggest that sunless tanning with DHA reduces photosensitivity in patients with EPP. Our hypothesis is that skin treated with DHA can tolerate twice the daylight dose compared to untreated skin before onset of skin symptoms. To validate this conclusion, we plan a randomized clinical trial to determine the effect of DHA application to reduce photosensitivity in patients with EPP under controlled clinical conditions. The study protocol for this trial is presented in the paper.


Assuntos
Fotoquimioterapia , Transtornos de Fotossensibilidade , Protoporfiria Eritropoética , Humanos , Protoporfiria Eritropoética/tratamento farmacológico , Di-Hidroxiacetona/uso terapêutico , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/uso terapêutico , Luz , Transtornos de Fotossensibilidade/tratamento farmacológico
2.
J Biochem Mol Toxicol ; 35(11): e22897, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34448514

RESUMO

Phosphine (PH3 ) is widely used as an insecticide and rodenticide. On the contrary, many cases of PH3 poisoning have been reported worldwide. Unfortunately, there is no specific antidote against PH3 toxicity. Disruption of mitochondrial function and energy metabolism is a well-known mechanism of PH3 cytotoxicity. Dihydroxyacetone (DHA) is an adenosine triphosphate supplying agent which significantly improves mitochondrial function. The current study was designed to evaluate DHA's effect on inhalational PH3 poisoning in an animal model. DHA was injected into BALB/c mice before and/or after the start of the PH3 inhalation. The cytochrome c oxidase activity was assessed in the animals' brain, heart, and liver exposed to PH3 (for 15, 30, and 60 min, with and without the antidote). The LC50 of PH3 was calculated to be 18.02 (15.42-20.55) ppm over 2 h of exposure. Pretreatment of DHA (1 or 2 g/kg) increased the LC50 of PH3 by about 1.6- or 3-fold, respectively. Posttreatment with DHA (2 g/kg) increased the LC50 of PH3 by about 1.4-fold. PH3 inhibited the activity of cytochrome c oxidase in the assessed organs. It was found that DHA treatment restored mitochondrial cytochrome c oxidase activity. These findings suggested that DHA could be an effective antidote for PH3 poisoning.


Assuntos
Di-Hidroxiacetona/uso terapêutico , Fosfinas/intoxicação , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/enzimologia , Complexo IV da Cadeia de Transporte de Elétrons/antagonistas & inibidores , Coração/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos BALB C
3.
Arh Hig Rada Toksikol ; 69(2): 169-177, 2018 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-29990298

RESUMO

Aluminium phosphide (AlP), a very toxic pesticide also known as the rice tablet, releases phosphine gas upon contact with water, moisture, or gastric acid. Its mortality rate in humans is 70-100 % due to cardiogenic shock and refractory hypotension. Dihydroxyacetone (DHA) is a simple ketonic carbohydrate, mainly used for sunless skin tanning. It also plays a beneficial role in the treatment of hypotension and cardiogenic shock by restoring blood volume and cellular respiration. The aim of this study was to investigate the its effect on the haemodynamics and electrocardiogram (ECG) in male rats poisoned with AlP. The animals were divided into the following groups: control (received 1 mL corn oil, orally), AlP (received 15 mg kg-1 AlP solved in corn oil, orally), AlP plus DHA (treated with 50 mg kg-1 of DHA 30 min after receiving AlP), and AlP plus N-acetyl cysteine (NAC) (treated with 200 mg kg-1 of NAC 30 min after receiving AlP). The animals were then anaesthetised and ECG, blood pressure, and heart rate were recorded for 120 min. Treatment with AlP alone and in combination with NAC was associated with progressive hypotension, tachycardia, and ECG disturbances in rats, resulting in 100 % mortality 3 h after poisoning. However, DHA achieved 100 % survival in the poisoned rats and prevented AlP-induced ECG and haemodynamic abnormalities. The main mechanism of DHA in the treatment of AlP poisoning is unclear, but the findings suggest the promising therapeutic potential of DHA against AlP poisoning.


Assuntos
Compostos de Alumínio/toxicidade , Di-Hidroxiacetona/uso terapêutico , Praguicidas/toxicidade , Fosfinas/toxicidade , Intoxicação/tratamento farmacológico , Choque Cardiogênico/induzido quimicamente , Choque Cardiogênico/tratamento farmacológico , Animais , Masculino , Ratos
7.
Dermatologica ; 150(6): 346-51, 1975.
Artigo em Inglês | MEDLINE | ID: mdl-1201808

RESUMO

Dihydroxyacetone (DHA) chemically induces long ultraviolet (UV) and/or visible photoprotection into the stratum corneum as demonstrated by (a) long UV protection of albino rats which were psoralen-photosensitized to black fluorescent light and (b) sunlight protection of five patients with long UV and/or visible photosensitivity. Previously, DHA treatment of skin was considered to provide no protection against UV. For clinical use, the combination of DHA and lawsone (2-hydroxy-1,4-naphthoquinone) is preferred to DHA alone, because it provides rapid, positive protection over a range extending from short UV into the visible region of sunlight.


Assuntos
Di-Hidroxiacetona/uso terapêutico , Luz/efeitos adversos , Naftoquinonas/uso terapêutico , Transtornos de Fotossensibilidade/prevenção & controle , Protetores Solares , Trioses/uso terapêutico , Raios Ultravioleta/efeitos adversos , Administração Tópica , Adolescente , Adulto , Animais , Criança , Di-Hidroxiacetona/administração & dosagem , Modelos Animais de Doenças , Combinação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Naftoquinonas/administração & dosagem , Transtornos de Fotossensibilidade/etiologia , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA